Gerner, Stefan T.
Huttner, Hagen B.
Article History
First Online: 29 May 2019
Compliance with Ethical Standards
:
: Hagen B. Huttner reports personal fees outside the submitted work from Boehringer Ingelheim (dabigatran, idarucizumab), Daiichi Sankyo (edoxaban), and CSL Behring (Beriplex—PCC). He also reports grants from Medtronic, Novartis, and UCB Pharma, outside the submitted work. Stefan T. Gerner declares no potential conflicts of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.